11.1 Information on toxicological effects
Mixture Acute toxicity
Acute toxicity estimate Oral - > 5,000 mg/kg (Calculation method)
Symptoms: Irritations of mucous membranes in the mouth, pharynx, oesophagus and gastrointestinal tract.
Acute toxicity estimate Inhalation - 4 h - > 10 mg/l - dust/mist(Calculation meth- od)
Symptoms: Possible symptoms:, mucosal irritations, Cough, Shortness of breath,
Possible damages:, damage of respiratory tract
Acute toxicity estimate Dermal - > 5,000 mg/kg (Calculation method)
Skin corrosion/irritation
Remarks: Mixture causes skin irritation.
Serious eye damage/eye irritation
Remarks: Mixture causes serious eye irritation.
Respiratory or skin sensitization
Classified based on available data. For more details, see section 2
Germ cell mutagenicity
Classified based on available data. For more details, see section 2
Carcinogenicity
Classified based on available data. For more details, see section 2
Reproductive toxicity
Classified based on available data. For more details, see section 2
Specific target organ toxicity - single exposure
Mixture may cause respiratory irritation.
Specific target organ toxicity - repeated exposure
Classified based on available data. For more details, see section 2
Aspiration hazard
Classified based on available data. For more details, see section 2
11.2 Additional Information
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.
Other dangerous properties can not be excluded.
Handle in accordance with good industrial hygiene and safety practice.
Components tri-sodium phosphate
Acute toxicity
LD50 Oral - Rat - female - > 2,000 mg/kg (OECD Test Guideline 420)
LC50 Inhalation - Rat - male and female - 4 h - > 0.83 mg/l - dust/mist (OECD Test Guideline 403)
Remarks: (in analogy to similar products)
The value is given in analogy to the following substances: sodium dihydrogen phosphate
LD50 Dermal - Rat - male and female - > 2,000 mg/kg (OECD Test Guideline 402)
Skin corrosion/irritation
Remarks: Irritating to skin.
Remarks: (ECHA)
Serious eye damage/eye irritation
Eyes - Rabbit
Result: Causes serious eye irritation.
(US-EPA)
Remarks: (ECHA)
Respiratory or skin sensitization
Local lymph node assay (LLNA) - Mouse
Result: negative (OECD Test Guideline 429)
Germ cell mutagenicity
Test Type: In vitro mammalian cell gene mutation test
Test system: mouse lymphoma cells
Result: negative
Test Type: Micronucleus test
Test system: Human lymphocytes
Result: negative
Carcinogenicity
Classified based on available data. For more details, see section 2
Reproductive toxicity
Classified based on available data. For more details, see section 2
Specific target organ toxicity - single exposure
Inhalation - May cause respiratory irritation.
Specific target organ toxicity - repeated exposure
Classified based on available data. For more details, see section 2
Aspiration hazard
Classified based on available data. For more details, see section 2
Pertussis toxin from Bordetella Pertussis Acute toxicity
Acute toxicity estimate Oral - 100.1 mg/kg (Expert judgment)
Acute toxicity estimate Inhalation - 4 h - 0.51 mg/l - dust/mist (Expert judgment)
Acute toxicity estimate Dermal - 300.1 mg/kg (Expert judgment)
Skin corrosion/irritation
Classified based on available data. For more details, see section 2
Serious eye damage/eye irritation
Classified based on available data. For more details, see section 2
Respiratory or skin sensitization
Classified based on available data. For more details, see section 2
Germ cell mutagenicity
Classified based on available data. For more details, see section 2
Carcinogenicity
Classified based on available data. For more details, see section 2
Reproductive toxicity
Classified based on available data. For more details, see section 2
Specific target organ toxicity - single exposure
Classified based on available data. For more details, see section 2
Specific target organ toxicity - repeated exposure
Classified based on available data. For more details, see section 2
Aspiration hazard
Classified based on available data. For more details, see section 2